VIDEO: Low-volume colonoscopy prep Plenvu well tolerated by patients
SAN ANTONIO — In this exclusive video from the American College of Gastroenterology Annual Meeting, Brooks D. Cash, MD, FACG, chief of the division of gastroenterology, hepatology, and nutrition at the University of Texas Health Science Center at Houston, discusses the results of a study on Plenvu, a low-volume colonoscopy prep.
“What we found with this prep, which is the lowest volume prep on the market today, is that patients were quite satisfied,” Cash told Healio Gastroenterology and Liver Disease. “Ninety-seven percent of patients actually consumed all or most of the prep.”
Researchers asked the approximately 1,600 patients included in the study about their tolerance of the prep, and Cash said 75% to 80% of the patients reported that the prep was extremely well tolerated and thought the volume of the prep was “absolutely appropriate.”
Additionally, investigators asked patients who previously used other preps to compare them with their experience with Plenvu (Salix Pharmaceuticals). Cash said that preference for Plenvu was as high as 75% among the patients.
“The important things we discovered from this study was that this was a well-tolerated prep and that patients are absolutely willing to do it again and also recommend it to their friends and family,” Cash said.
Cash BD, et al. P0372. Presented at: American College of Gastroenterology Annual Meeting; Oct. 25-30, 2019; San Antonio.
Disclosures: Cash reports serving on the advisory and committee and speakers bureau at and consulting for Allergan, Ironwood, Salix, Shire and Takeda.